Showing 501 - 520 results of 1,448 for search '(( significant decrease decrease ) OR ( significant protective decrease ))~', query time: 0.39s Refine Results
  1. 501
  2. 502

    Demographic and ocular features. by Mingxi Shao (10066570)

    Published 2025
    “…</p><p>Results</p><p>In the PCG group, H<sub>2</sub>O<sub>2</sub> and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H<sub>2</sub>O<sub>2</sub> (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”
  3. 503

    Machine learning model to diagnose PCG. by Mingxi Shao (10066570)

    Published 2025
    “…</p><p>Results</p><p>In the PCG group, H<sub>2</sub>O<sub>2</sub> and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H<sub>2</sub>O<sub>2</sub> (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”
  4. 504

    ROC curves of TAS + SOD + MDA to diagnose PCG. by Mingxi Shao (10066570)

    Published 2025
    “…</p><p>Results</p><p>In the PCG group, H<sub>2</sub>O<sub>2</sub> and MDA levels were notably higher than in controls (p < 0.001, <i><i>p</i> </i>= 0.020), while TAS levels were significantly lower (p = 0.043). Adjusting for age and gender, the serum TAS (OR = 0.07, 95% CI 0.01–0.85, <i><i>p</i></i> = 0.037), H<sub>2</sub>O<sub>2</sub> (OR = 1.21, 95% CI 1.09–1.35, <i><i>p</i></i> = 0.001) and MDA (OR = 1.17, 95% CI 1.00–1.34, <i><i>p</i></i> = 0.034) were determined to be independent risk/protective factors for PCG. …”
  5. 505

    Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy by Ya-yin Tan (21448519)

    Published 2025
    “…In experiments with SV40-transformed mouse glomerular mesangial cells (MCs), PCK1 and PPARγ protein expression levels were significantly decreased in polymeric IgA1 (pIgA1)-stimulated MCs, which contrasts with the increased expression of inflammatory and fibrotic factors. …”
  6. 506

    Primers for qPCR. by Xiaoyi Shi (3825754)

    Published 2024
    “…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”
  7. 507

    S1 Raw data - by Xiaoyi Shi (3825754)

    Published 2024
    “…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”
  8. 508

    The chemical structure of melatonin. by Xiaoyi Shi (3825754)

    Published 2024
    “…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”
  9. 509

    The funnel plot of mortality rate. by Lei Wang (6656)

    Published 2025
    “…Compared with the control group (placebo), high-dose intravenous iron significantly decreased the rate of postoperative red blood cell transfusion among patients undergoing cardiac surgery (risk ratio 0.69, 95% confidence interval [CI] 0.52–0.91, P = 0.009, I<sup>2</sup> = 61%, n = 975, certainty of evidence: moderate). …”
  10. 510

    General Characteristics of the Included Studies. by Lei Wang (6656)

    Published 2025
    “…Compared with the control group (placebo), high-dose intravenous iron significantly decreased the rate of postoperative red blood cell transfusion among patients undergoing cardiac surgery (risk ratio 0.69, 95% confidence interval [CI] 0.52–0.91, P = 0.009, I<sup>2</sup> = 61%, n = 975, certainty of evidence: moderate). …”
  11. 511

    pHI for net status. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  12. 512

    Combined net integrity PBO and LLINs-PLOS1. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  13. 513

    Factors affecting pyrethroid-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  14. 514

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  15. 515

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  16. 516

    Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  17. 517

    Net bioefficacy data. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  18. 518

    House structure and status. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  19. 519

    LLINs hole positions over time. by Job Oyweri (22041452)

    Published 2025
    “…</p><p>Conclusion</p><p>Both physical integrity and bioefficacy of LLINs declined significantly within 18 months. The findings demonstrate that not all nets in the field offer maximum protection by this time point, calling for net care education and further evaluation of PBO-LLINs especially in pyrethroid-resistant regions.…”
  20. 520

    Table_3_Combinatorial protection of cochlear hair cells: not too little but not too much.docx by Arwa Kurabi (344167)

    Published 2024
    “…All compounds were added at a dosage below that required for significant protection in the assay, and only this single dose was then employed. …”